• Mentari Therapeutics published pro forma financial statements reflecting its merger with InMed Pharmaceuticals, which closed November 6, 2026.
• Cash totaled $478.12 million as of June 30, 2026, reflecting $490 million in pre-closing financing, including convertible notes.
• Total assets reached $478.78 million, against liabilities of $11.42 million.
• Net loss from continuing operations totaled $37.29 million for the six months ended June 30, 2026; research spending reached $31.1 million.
• For 2025, net loss from continuing operations was $26.9 million, with operating expenses of $27.54 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mentari Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-455640), on November 10, 2026, and is solely responsible for the information contained therein.